Share this Page:
The following video from Practice Update is an interview with Dr Eric Jonasch, Professor at the Department of Genitourinary Medical Oncology in the Division of Cancer Medicine, and Director of the VHL Clinical Center at the University of Texas’ MD Anderson Cancer Center. Dr Jonasch is also a Board Director at the International Kidney Cancer Coalition (IKCC).
During this interview, Dr Jonasch talks about a trial of an alternative dose schedule for sunitinib in patients with metastatic renal cell carcinoma (RCC), and the efficacy of a 2/1 schedule versus the traditional 4/2 schedule. He also talks about the results from studies comparing sunitinib with immunotherapy checkpoint inhibitors.